Boston, United States
Prilenia, founded in 2018, is a promising clinical-stage biotech company advancing the landscape of treatments for neurodegenerative and neurodevelopmental disorders. With headquarters in the United States, and operations spanning Naarden, the Netherlands, Herzliya, Israel, and Boston, MA, Prilenia is strategically positioned at the intersection of innovation and science in the Biotechnology, Health Care, Life Sciences, and Pharmaceutical industries.
At the core of Prilenia’s efforts is Pridopidine, a pioneering oral drug candidate with the potential to transform treatment paradigms for multiple movement disorders. Currently, it is being tested for Huntington’s disease in a global Phase 3 PROOF-HD trial and for ALS in a Phase 2/3 HEALEY platform trial.
With leadership from Dr. Michael Hayden, a seasoned figure in biotech innovations, and recent $43.00M Series B funding led by notable investors such as Forbion and Sands Capital Ventures, Prilenia presents a compelling opportunity for stakeholders in the biotech investment sector.
